15 Dec 2022 - 18 Dec 2022
09:00 AM - 06:00 PM
6th Annual Year End Review in Lung Cancer
Program Director: Dr Kumar Prabhash
6th Annual Year End Review in Lung Cancer, 2022
ALK/ROS/RET/NTRK/BRAF - 18 Dec 2022
Date : 18 Dec 2022
| Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC | 10:00 AM - 02:00 PM |
| Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC | 10:00 AM - 02:00 PM |
| NSCLC is a heterogeneous set of diseases defined by oncogenic drivers | 10:00 AM - 02:00 PM |
| Brigatinib versus Crizotinib in ALK Inhibitor Naive Advanced ALK Positive NSCLC | 10:00 AM - 02:00 PM |
| Clinical implications of cardiotoxicity and pharmacokinetics of alectinib | 10:00 AM - 02:00 PM |
| Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients | 10:00 AM - 02:00 PM |
| ALK Rearrangements in Lung Cancer | 10:00 AM - 02:00 PM |
| Phase II study of Lorlatinib in Patients with Anaplastic Lymphoma Kinase | 10:00 AM - 02:00 PM |
| Panel Discussion - ALESIA 5 year update and Optimal Sequencing of TKIs | 10:00 AM - 02:00 PM |
| No Topic | 10:00 AM - 02:00 PM |
| The Phase II Study of Unecritinib TQ B3101 monotherapy in the 1L treatment | 10:00 AM - 02:00 PM |
| Durability of Efficacy and Safety with Selpercatinib in Patients with RET Fusion | 10:00 AM - 02:00 PM |
| The efficacy and safety of Taletrectinib in patients with TKI naive | 10:00 AM - 02:00 PM |
| NVL 520 ROS TKI | 10:00 AM - 02:00 PM |
| RET MAP An International multi center study on clinicopathologic features | 10:00 AM - 02:00 PM |
| Capmatinib in MET exon 14 mutated advanced NSCLC updated results from the GEOMETRY | 10:00 AM - 02:00 PM |
| Tepotinib in asian patients with advanced NSCLC with MET exon 14 skipping | 10:00 AM - 02:00 PM |
| Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer | 10:00 AM - 02:00 PM |
| Safety and efficacy of Pralsetinib in RET fusion positive | 10:00 AM - 02:00 PM |
| RET fused NSCLC State of the art treatment of advanced disease | 10:00 AM - 02:00 PM |
| Panel Discussion - Management of ROS and RET positive NSCLC | 10:00 AM - 02:00 PM |
| Overview of the two indications of Entrectinib | 10:00 AM - 02:00 PM |
| Entrectinib in chinese patients with Locally advanced metastatic ROS1 fusion | 10:00 AM - 02:00 PM |
| Updated efficacy and safety of larotrectinib in patients with tropomyosin | 10:00 AM - 02:00 PM |
| Amivantamab in NSCLC patients with MET exon 14 askipping mutation | 10:00 AM - 02:00 PM |
| Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 | 10:00 AM - 02:00 PM |
| Panel Discussion - Case Discussion (NTRK/MET) | 10:00 AM - 02:00 PM |
| Closing Remarks | 10:00 AM - 02:00 PM |
Locally Advance Lung Cancer - 17 Dec 2022
Date : 17 Dec 2022
| Twice daily tRT by IMRT compasred with SIB IRT with concurrent chemotherapy | 09:00 AM - 06:00 PM |
| Long term Survival & Competing Rsks of Death in the ESPATUE Randomized Phase III | 09:00 AM - 06:00 PM |
| Impact of radiation dose to the immune cells in unresectable or stage III | 09:00 AM - 06:00 PM |
| Exposure of the heart in lung cancer radiation therapy A Systematic review | 09:00 AM - 06:00 PM |
| Panel Discussion - Local Therapy Locally Advanced | 09:00 AM - 06:00 PM |
| Nivolumab + Chemotherapy Vs Chemotherapy as NAT in Resectable Stage III | 09:00 AM - 06:00 PM |
| Overall survival & Biomarker analysis of Neoadjuvant Nivolumab Plus Chemotherapy | 09:00 AM - 06:00 PM |
| Pre treatment ctDNA Levels Significantly Predicts of OS & PFS in NADIM II Trial | 09:00 AM - 06:00 PM |
| Sugemalimab vs Placebo after cCRT or sCRT in Patients with Unresectable stage III | 09:00 AM - 06:00 PM |
| Consolidation nivolumab plus ipilimumab or nivolumab alone following | 09:00 AM - 06:00 PM |
| Proton therapy & concurrent Chemotherapy in stage III NSCLC | 09:00 AM - 06:00 PM |
| Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC | 09:00 AM - 06:00 PM |
| Impact of grade 2 Pneumonitis on Patient Reported outcomes with Durvalumab | 09:00 AM - 06:00 PM |
| Association of Driver Oncogene Variations with Outcomes in Patients | 09:00 AM - 06:00 PM |
| Panel Discussion - Durvalumab in Stage III NSCLC | 09:00 AM - 06:00 PM |
First line IO or Long term IO data - 17 Dec 2022
Date : 17 Dec 2022
| Outcomes of 1L immune checkpoint inhibitors with or without chemotherapy | 09:00 AM - 03:00 PM |
| Pembrolizumab versus best supportive care survival outcomes in ECOG performance | 09:00 AM - 03:00 PM |
| Effectiveness of PD L1 inhibitors alone or in combination with platinum doublet | 09:00 AM - 03:00 PM |
| Adoption of Extended Interval Dosing of Single Agent Pembrolizumab and Comparative | 09:00 AM - 03:00 PM |
| IPSOS Results from a Phase III Study of first line1L atezolizumab vs single agent | 09:00 AM - 03:00 PM |
| Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a 1L | 09:00 AM - 03:00 PM |
| Association Between Smoking History and Overall Survival in Patients Receiving | 09:00 AM - 03:00 PM |
| Pre Existing Autoimmune Disease and Mortality in Patients Treated with Anti PD | 09:00 AM - 03:00 PM |
| Camrelizumab monotherapy or plus apatinib for PD L1 positive advanced pulmonary | 09:00 AM - 03:00 PM |
| Serplulimab a novel anti PD 1 antibody plus chemotherapy versus chemotherapy | 09:00 AM - 03:00 PM |
| Panel Discussion - Are All ICI the same | 09:00 AM - 03:00 PM |
| Phase II Randomised Study of Ramucirumab & Pembrolizumab Versus Standard of care | 09:00 AM - 03:00 PM |
| Cabozantinib C plus atezolizumab A or C alone in patients pts with advanced | 09:00 AM - 03:00 PM |
| Results of a phase II study investigating eftilagimod alpha soluble LAG 3 protein | 09:00 AM - 03:00 PM |
| Pooled Analysis of Outcomes with Second Course Pembrolizumab Across 5 Phase 3 | 09:00 AM - 03:00 PM |
| HUDSON An Open Label, Multi Drug, Biomarker Directed Phase 2 Study in NSCLC | 09:00 AM - 03:00 PM |
| IMpower010 Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB IIIA | 09:00 AM - 03:00 PM |
Low dose & Alternate IO - 17 Dec 2022
Date : 17 Dec 2022
| Low dose & Alternate IO | 03:00 PM - 08:00 PM |
| Comparative Effectiveness and Safety of Standard Dose and Low Dose Pembrolizumab | 03:00 PM - 08:00 PM |
| Panel Discussion - Redefining the management of NSCLC with Atezolizumab | 03:00 PM - 08:00 PM |
| Primary Data from DESTINY Lung01 A Phase 2 Trial of Trastuzumab DerruxtecanT DXd | 03:00 PM - 08:00 PM |
| Indirect comparison of Mobocertinib trial data vs real world data in patients | 03:00 PM - 08:00 PM |
| Poziotinib for Patients With HER2 Exon 20 Mutant Non Small Cell Lung Cancer Results | 03:00 PM - 08:00 PM |
| Hidden EGFR Threat Role of Amivantamab | 03:00 PM - 08:00 PM |
| Panel Discussion - Hidden EGFR Threat Role of Amivantamab | 03:00 PM - 08:00 PM |
| Panel Discussion - Piccing Right VAD in Cancer Patients | 03:00 PM - 08:00 PM |
| Dissecting Molecular differences between EGFR Exon 19 & 21 L858R mutations | 03:00 PM - 08:00 PM |
| Nanosomal docetaxel lipid suspension (NDLS) monotherapy is effective | 03:00 PM - 08:00 PM |
Early Stage Lung Cancer - 16 Dec 2022
Date : 16 Dec 2022
| Vascular invasion in Stage I Lung adenocarcinoma Implications | 09:00 AM - 06:00 PM |
| A Systematic Review into the Radiologic Features Predicting Local Recurrence | 09:00 AM - 06:00 PM |
| Chest CT Scan+CXR versus CXR for follow up | 09:00 AM - 06:00 PM |
| Lobar versus Sublobar Resection in the Elderly for Early Lung Cancer | 09:00 AM - 06:00 PM |
| RVLob Trial Short Term Results | 09:00 AM - 06:00 PM |
| Comparison of SBRT and RFA for Early Stage NSCLC A Systematic review | 09:00 AM - 06:00 PM |
| Panel Discussion - Local Therapy Issues | 09:00 AM - 06:00 PM |
| Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine | 09:00 AM - 06:00 PM |
| 86P Aumolertinib as adjuvant therapy in postoperative EGFR mutated | 09:00 AM - 06:00 PM |
| Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB IIIA | 09:00 AM - 06:00 PM |
| Patients Preferences for Adjuvant Osimertinib In Non Small Cell Lung Cancer | 09:00 AM - 06:00 PM |
| Panel discussion Adjuvant Systemic Therapy-TKI | 09:00 AM - 06:00 PM |
| Panel Discussion Systemic therapy in Operable NSCLC role for CPI in this setting | 09:00 AM - 06:00 PM |
| Neoadjuvant Nivolumab plus Platium Doublet Chemotherapy vs Chemo for resectable | 09:00 AM - 06:00 PM |
| Pembrolizumab versus Placebo as adjuvant therapy for completely resected IV IIIA | 09:00 AM - 06:00 PM |
| Nivolumab + platinum doublet Chemotherapy vs Chemotherapy as neoadjuvant treatment | 09:00 AM - 06:00 PM |
| Neoadjuvant nivolumab in early stage non stage non small cell lung cancer | 09:00 AM - 06:00 PM |
Driver Mutation Part 1: EGFR - 16 Dec 2022
Date : 16 Dec 2022
| Bevacizumab plus erlotinib versus erlotinib alone in Japenese patients | 09:00 AM - 06:00 PM |
| Furmonertinib versus gefitinib in treatment naive EGFR mutated non small cell lung cancer | 09:00 AM - 06:00 PM |
| 7MO Oritinib a third generation EGFR tyrosine kinase inhibitor in locally advanced | 09:00 AM - 06:00 PM |
| Updated Analysis of NEJ009 Gefitinib Alone Versus Gefitinib Plus Chemotherapy | 09:00 AM - 06:00 PM |
| Randomized Trial of first Line Tyrosine Kinase Inhibitor with or without Radiotherapy | 09:00 AM - 06:00 PM |
| Sintilimab In Combination With Anlotinib In Non-Small Cell Lung Cancer Patients With Uncommon EGFR Mutations | 09:00 AM - 06:00 PM |
| Panel Discussion - EGFR mutant NSCLC 1st Line Long Term Outcomes | 09:00 AM - 06:00 PM |
| Simultaneous Tissue and Liquid Next-generation Sequencing after First-line EGFR Tyrosine Kinase Inhibitors Resistance in Advanced NSCLC | 09:00 AM - 06:00 PM |
| Real World Landscape of EGFR C797X Mutation as a Resistance Mechanism | 09:00 AM - 06:00 PM |
| A phase II study of Atezolizumab in combination with bevacizumab | 09:00 AM - 06:00 PM |
| Durvalumab plus chemotherapy in patients with advanced EGFR mutation positive | 09:00 AM - 06:00 PM |
| A Randomised phase II Study of Osimertinib and Bevacizumab Versus Bevacizumab | 09:00 AM - 06:00 PM |
| Capmatinib plus osimertinib versus platinumpermetrexed doublet Chemotherapy | 09:00 AM - 06:00 PM |
| BBT 176 A 4th Generation EGFR TKI for Progressed NSCLC After EGFR TKI Therapy | 09:00 AM - 06:00 PM |
| Panel Discussion - EGFR TKI Resistance | 09:00 AM - 06:00 PM |
| Optimization of treatment options for EGFR mutant Stage III Unresectable NSCLC | 09:00 AM - 06:00 PM |
| Once daily versus twice daily chemoradiation for limited stage small cell | 09:00 AM - 06:00 PM |
| CAPSTONE Trial | 09:00 AM - 06:00 PM |
| Primary analysis from the phase 2 study of continuous talazoparib TALA plus | 09:00 AM - 06:00 PM |
| Comparison of quality of life in patients randomized to high dose once daily QD | 09:00 AM - 06:00 PM |
| SKYCSRAPER 02 Primary results of a phase III randomized double blind | 09:00 AM - 06:00 PM |
| Panel Discussion - Optimal Management ES SCLC Case based Discussion | 09:00 AM - 06:00 PM |
| Development of a rural Comprehensive Cancer Centre | 09:00 AM - 06:00 PM |
| Role of Romiplostim in Chemotherapy induced Thrombocytopenia | 09:00 AM - 06:00 PM |
NGO Workshop - 15 Dec 2022
Date : 15 Dec 2022
| Almost all the patients and caregivers want Lung Connect to continue | 10:00 AM - 02:00 PM |
| Welcome & Introduction | 10:00 AM - 02:00 PM |
| What are the needs of Lung Cancer patients & caregiver | 10:00 AM - 02:00 PM |
| Evolving Lung Cancer Treatment clinical research and role of NGOs PAG | 10:00 AM - 02:00 PM |
| Using Lung Connect Digital Platforms to spread awareness | 10:00 AM - 02:00 PM |
| Using Lung Connect Digital Platforms to increase disease education | 10:00 AM - 02:00 PM |
| How Lung Connect as a platform can be replicated beyond Tata Mumbai to support more | 10:00 AM - 02:00 PM |
| Participants will be divided into 4 subgroups and will brainstorm and will come up w | 10:00 AM - 02:00 PM |
| Almost all the patients and caregivers want Lung Connect to continue and expand fur | 10:00 AM - 02:00 PM |
| Way Forward and summary | 10:00 AM - 02:00 PM |
Nurses Workshop - 15 Dec 2022
Date : 15 Dec 2022
| NOVEL APPROCHES UPDATES AND PERSPECTIVE FOR LUNG CANCER NURSING | 03:00 PM - 06:00 PM |
| Promoting Early Diagnosis of Lung Cancer | 03:00 PM - 06:00 PM |
| Challenges in Diagnosis and Treatment of Lung Cancer | 03:00 PM - 06:00 PM |
| Advances in Radiation Therapy in Treatment of Lung Cancer | 03:00 PM - 06:00 PM |
| Early Palliative Care for Patients with Lung Cancer | 03:00 PM - 06:00 PM |
| Oncologic Thoracic Emergencies of Patients with Lung Cancer | 03:00 PM - 06:00 PM |
| Strides in Supportive Care | 03:00 PM - 06:00 PM |
Radiology workshop - 15 Dec 2022
Date : 15 Dec 2022
| Recent Developments on Molecular Diagnosis of Lung Cancer | 06:30 PM - 08:30 PM |
| Current Practice and Emerging Breakthroughs in AI Imaging Radiomics in Lung Cancer | 06:30 PM - 08:30 PM |
| Image Guided Tissue Sampling | 06:30 PM - 08:30 PM |
| What's New in Thoracic Interventional Oncology | 06:30 PM - 08:30 PM |
| Chemotherapy Targeted Therapy and Immuno Therapy How to Access | 06:30 PM - 08:30 PM |
| Chakraborty Practice Updates in Lung Cancer Imaging Guide lined and Research | 06:30 PM - 08:30 PM |
| Panel Discussion Lung Cancer Case Management Evolving Role of Mulitimodality | 06:30 PM - 08:30 PM |
Program Director:
Dr Kumar Prabhash
Contact Person
Garima Vashishtha
info@hcmpl.com
8178985238
Download